Sotera Health Company (SHC)

In the past six months, Sotera Health's stock price has been impacted by several events. The announcement of Q4 2025 and full-year 2025 earnings in February 2026 led to a share price decrease despite positive results. A secondary offering in March 2026 also drew a negative market reaction. The appointment of Richard G. Kyle and Kenneth D. Krause to the board of directors saw a modestly positive market move. The release of strong Q1 2026 results and the announcement of a CEO transition in May 2026 resulted in a stock decrease. In March 2026, all eight bellwether cases related to ethylene oxide litigation were dismissed in Georgia.

The demand for Sotera Health's services is generally consistent due to ongoing needs in medical device manufacturing, pharmaceuticals, and food safety, rather than being highly seasonal. Localized weather impacts in the U.S. during Q1 resulted in a 1.7% headwind to Sterigenics volumes. Nordion's revenue in Q4 2025 saw an expected decrease due to the timing of cobalt-60 harvest schedules, indicating some timing-related fluctuations in that segment.

Sotera Health Co. is a global provider of sterilization solutions, lab testing, and advisory services for the healthcare industry, operating with the mission of "Safeguarding Global Health®". The company operates in the Healthcare sector, specifically in the Diagnostics & Research industry. Its business is structured around three segments: Sterigenics, which provides outsourced sterilization and irradiation services; Nordion, which specializes in the production and supply of Cobalt-60 and gamma irradiators; and Nelson Labs, which offers outsourced microbiological and analytical chemistry testing and advisory services.

Sotera Health has a significant global presence, operating more than 63 facilities across 13 countries and serving over 5,000 customers in more than 50 countries. The United States is the largest revenue generator, followed by Canada, Europe, and other regions.

Sotera Health has a long-established reputation for reliability and safety in global health. The company's reputation has been influenced by ethylene oxide litigation, operational excellence and growth, and a planned leadership transition. Recent developments in March 2026 saw the dismissal of all eight bellwether cases in Georgia, which could be a positive for its reputation regarding these specific legal challenges.

Sotera Health Company's ownership is predominantly institutional, with institutional investors holding the majority of shares. Major institutional owners include Warburg Pincus LLC, Darsana Capital Partners LP, GTCR LLC, Vanguard Group Inc., BlackRock, Inc., Sachem Head Capital Management LP, Janus Henderson Group Plc, and State Street Corp. Individual investors hold approximately 19% ownership, while insiders own 15.36% of the company's stock.